1. Home
  2. PRPL vs BMEA Comparison

PRPL vs BMEA Comparison

Compare PRPL & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRPL
  • BMEA
  • Stock Information
  • Founded
  • PRPL 2010
  • BMEA 2017
  • Country
  • PRPL United States
  • BMEA United States
  • Employees
  • PRPL N/A
  • BMEA N/A
  • Industry
  • PRPL Home Furnishings
  • BMEA Biotechnology: Pharmaceutical Preparations
  • Sector
  • PRPL Consumer Discretionary
  • BMEA Health Care
  • Exchange
  • PRPL Nasdaq
  • BMEA Nasdaq
  • Market Cap
  • PRPL 89.8M
  • BMEA 96.9M
  • IPO Year
  • PRPL N/A
  • BMEA 2021
  • Fundamental
  • Price
  • PRPL $0.73
  • BMEA $1.28
  • Analyst Decision
  • PRPL Hold
  • BMEA Strong Buy
  • Analyst Count
  • PRPL 1
  • BMEA 7
  • Target Price
  • PRPL $1.00
  • BMEA $8.71
  • AVG Volume (30 Days)
  • PRPL 639.4K
  • BMEA 1.4M
  • Earning Date
  • PRPL 11-04-2025
  • BMEA 11-04-2025
  • Dividend Yield
  • PRPL N/A
  • BMEA N/A
  • EPS Growth
  • PRPL N/A
  • BMEA N/A
  • EPS
  • PRPL N/A
  • BMEA N/A
  • Revenue
  • PRPL $457,012,000.00
  • BMEA N/A
  • Revenue This Year
  • PRPL N/A
  • BMEA N/A
  • Revenue Next Year
  • PRPL $11.87
  • BMEA N/A
  • P/E Ratio
  • PRPL N/A
  • BMEA N/A
  • Revenue Growth
  • PRPL N/A
  • BMEA N/A
  • 52 Week Low
  • PRPL $0.56
  • BMEA $1.22
  • 52 Week High
  • PRPL $1.29
  • BMEA $7.50
  • Technical
  • Relative Strength Index (RSI)
  • PRPL 41.26
  • BMEA 38.07
  • Support Level
  • PRPL $0.69
  • BMEA $1.24
  • Resistance Level
  • PRPL $0.84
  • BMEA $1.42
  • Average True Range (ATR)
  • PRPL 0.07
  • BMEA 0.08
  • MACD
  • PRPL -0.00
  • BMEA 0.01
  • Stochastic Oscillator
  • PRPL 31.96
  • BMEA 28.10

About PRPL Purple Innovation Inc.

Purple Innovation Inc is a comfort innovation company. The company designs, manufactures and sells a range of comfort technology offerings, including mattresses, a pillow, cushions, sheets, bed platforms and other products. The Company has one reportable segment that operates an omni-channel distribution which allows the Company to offer a seamless shopping experience to its customers across multiple sales channels. It sells its products through its direct-to-consumer e-commerce channels, retail brick-and-mortar wholesale partners, Purple showrooms, and third-party online retailers.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Share on Social Networks: